Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06369792
Status:
RECRUITING
Last Update Posted:
2024-04-17
First Post:
2024-04-12
Brief Title:
PROSPECTIVE EVALUATION OF BLOOD BIOMARKERS AS AN AID TO DIAGNOSTIC AND TREATMENT IN DRUG-NAIVE PATIENTS WITH DEPRESSION
Sponsor:
Les Toises - Psychiatry and Psychotherapy Center
Organization:
Les Toises - Psychiatry and Psychotherapy Center
Study Overview
Official Title:
EVALUATION PROSPECTIVE DE LAIDE AU DIAGNOSTIC ET AU TRAITEMENT PAR BIOMARQUEURS SANGUINS CHEZ DES PATIENTS DRUG-NAÏFS AMBULATOIRES SOUFFRANT DE DEPRESSION
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an observational non-interventional prospective study carried out in drug-naïve outpatients who start a treatment with escitalopram fluoxetine sertraline or quetiapine Five blood samples are collected ie before initiating the drug and then after 1 2 4 and 8 weeks of treatment It does not affect the choice or the treatment dose The primary objective of this study is to measure the association between the EDIT-B editing signature and response to pharmacological treatment in drug-naïve patients Results of this research could provide an aid to early diagnosis optimize pharmacological treatment and guide clinical practice towards individualized treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None